BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36195857)

  • 1. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma.
    Wu G; Yang Y; Ye R; Yue H; Zhang H; Huang T; Liu M; Zheng Y; Wang Y; Zhou Y; Guo Q
    BMC Cancer; 2022 Oct; 22(1):1036. PubMed ID: 36195857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
    Zhao QJ; Zhang J; Xu L; Liu FF
    World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
    Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
    BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma.
    Lin X; Yang S
    Adv Clin Exp Med; 2022 Oct; 31(10):1099-1109. PubMed ID: 35581934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
    Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
    Front Immunol; 2021; 12():719175. PubMed ID: 34603293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
    Xu Q; Wang Y; Huang W
    Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
    Yan J; Zhou C; Guo K; Li Q; Wang Z
    J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma.
    Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J
    J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
    Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
    Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
    Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Front Genet; 2023; 14():1056000. PubMed ID: 36845390
    [No Abstract]   [Full Text] [Related]  

  • 18. A ferroptosis-associated lncRNAs signature predicts the prognosis of hepatocellular carcinoma.
    Wang D; Zhang L; Zhang Y; Zhang Y; Xu S
    Medicine (Baltimore); 2022 Jul; 101(28):e29546. PubMed ID: 35839000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
    Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
    Front Genet; 2021; 12():785185. PubMed ID: 34917132
    [No Abstract]   [Full Text] [Related]  

  • 20. Exploring Prognostic Signatures of Hepatocellular Carcinoma and the Potential Implications in Tumor Immune Microenvironment.
    Chen H; Jiang Z; Yang B; Yan G; Wang X; Zang S
    Comb Chem High Throughput Screen; 2022; 25(6):998-1004. PubMed ID: 33687891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.